HPV immunity as markers of protection against infection
- Research Opportunity
- Honours, Master of Biomedical Science
- Number of Honour Places Available
- Number of Master Places Available
- Royal Children’s Hospital/Murdoch Childrens Research Institute
|Doctor Zheng Quan Tohfirstname.lastname@example.org|
|Associate Professor Paul Licciardiemail@example.com||Personal web page|
Summary This project aims to examine the immunological response following HPV vaccination using a combination of techniques including flow cytometry, PCR and possibly RNA-sequencing.
Cervical cancer is the fourth most common cancer in women worldwide, caused by infections with the human papillomavirus (HPV), with highest rates in low- and middle-income countries. Most cases (70%) are due to oncogenic HPV types 16 and 18 which are included in the two widely used prophylactic HPV vaccines, 2vHPV (Cervarix, GSK Biologicals) or 4vHPV (Gardasil, Merck) given as a 3-dose schedule over six months. We have recently completed a cohort study in Fijian girls who received 1, 2 or 3 doses of 4vHPV six years earlier and who subsequently were boosted with a dose of 2vHPV. This project aims to examine the immunological response following HPV vaccination using a combination of techniques including flow cytometry, PCR and possibly RNA-sequencing.
Faculty Research Themes
School Research Themes
Honours, Master of Biomedical Science
Students who are interested in joining this project will need to consider their elegibility as well as other requirements before contacting the supervisor of this research
For further information about this research, please contact a supervisor.
Research NodeRoyal Children’s Hospital/Murdoch Childrens Research Institute
MDHS Research library
Explore by researcher, school, project or topic.